Interleukin-6 receptor shedding is enhanced by interleukin-1β and tumor necrosis factor α and is partially mediated by tumor necrosis factor α-converting enzyme in osteoblast-like cells

Arthritis and Rheumatism

Volumn 52, Issue 1, 2005, Pages 84-93

  Franchimont, Nathalie ^a   Lambert, Cécile ^a   Huynen, Pascale ^a   Ribbens, Clio ^a   Relic, Biserka ^a   Chariot, Alain ^a   Bours, Vincent ^a   Piette, Jacques ^a   Merville, Marie Paule ^a   Malaise, Michel ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; CYCLOHEXIMIDE; EGTAZIC ACID; HYDROXAMIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; RU 36156; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; BONE DEVELOPMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOASSAY; INFLAMMATION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN FUNCTION; RNA SPLICING; WESTERN BLOTTING;

ADAM PROTEINS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-1; METALLOENDOPEPTIDASES; OSTEOBLASTS; RECEPTORS, INTERLEUKIN-6; RECOMBINANT PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; SOLUBILITY; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 19944430946     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20727     Document Type: Article

References (54)

1. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
2. Romas T, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6.
3. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
4. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1β and tumor necrosis factor-α but not interleukin-6 stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255-9.
5. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002;4 Suppl 3:S233-42.
6. Wong PK, Campbell IK, Egan PJ, Ernst M, Wicks IP. The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum 2003;48:1177-89.
7. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1-7.
8. Hing L, Carlson L, Siebenlist U, Boyce BF. Mechanisms by which NF-κB regulate osteoclast numbers [abstract]. Bone 1998;23 Suppl 1:S190.
9. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin-6 is required for the development of collagen-induced arthritis. J Exp Med 1998;187:461-8.
10. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, et al. Interleukin-6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 1998;95:8222-6.
11. Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999;42:1635-43.
12. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996;11:88-95.
13. Helle M, Brakenhoff JP, de Groot ER, Aarden LA. Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol 1988;18:957-9.
14. Littlewood AJ, Russell J, Harvey GR, Hughes DE, Russell RG, Gowen M. The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology 1991;129:1513-20.
15. Franchimont N, Durant D, Rydziel S, Canalis E. Platelet-derived growth factor induces interleukin-6 transcription in osteoblasts through the activator protein-1 complex and activating transcription factor-2. J Biol Chem 1999;274:6783-9.
16. Franchimont N, Rydziel S, Canalis E. Transforming growth factor-β increases interleukin-6 transcripts in osteoblasts. Bone 2000;26:249-53.
17. Udagawa N, Takahashi N, Katagiri T, Tamura T, Wada S, Findlay DM, et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 1995;182:1461-8.
18. Rose-John S, Ehlers M, Grotzinger J, Mullberg J. The soluble interleukin-6 receptor. Ann N Y Acad Sci 1995;762:207-20.
19. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001;15:43-58.
20. Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992;4:96-100.
21. Mullberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993;23:473-80.
22. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 1993;90:11924-8.
23. Franchimont N, Rydziel S, Delany AM, Canalis E. Interleukin-6 and its soluble receptor cause a marked induction of collagenase 3 expression in rat osteoblast cultures. J Biol Chem 1997;272:12144-50.
24. Franchimont N, Rydziel S, Canalis E. Interleukin 6 is autoregulated by transcriptional mechanisms in cultures of rat osteoblastic cells. J Clin Invest 1997;100:1797-803.
25. Bellido T, Stahl N, Farruggella TJ, Borba V, Yancopoulos GD, Manolagas SC. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J Clin Invest 1996;97:431-7.
26. Black RA, Rauch CT, Kozloosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumor necrosis factor-α from cells. Nature 1997;385:729-33.
27. Ohta S, Harigai M, Tanaka M, Kawaguchi Y, Sugiura T, Takagi K, et al. Tumor necrosis factor-α (TNF-α) converting enzyme contributes to production of tumor necrosis factor-α in synovial tissues from patients with rheumatoid arthritis. J Rheumatol 2001;28:1756-63.
28. Althoff K, Reddy P, Voltz N, Rose-John S, Mullberg J. Shedding of interleukin-6 receptor and tumor necrosis factor α: contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem 2000;267:2624-31.
29. Mullberg J, Vollmer P, Althoff K, Marz P, Rose-John S. Membrane protein secretases: generation and function of the soluble interleukin-6 receptor. Biochem Soc Trans 1999;27:211-9.
30. Gallea-Robache S, Morand V, Millet S, Bruneau JM, Bhatnagar N, Chouaib S, et al. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine 1997;9:340-6.
31. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, et al. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274:13613-8.
32. Doggrell SA. TAGE inhibition: a new approach to treating inflammation. Expert Opin Investig Drugs 2002;11:1003-6.
33. Newton RC, Solomon KA, Covington MB, Decicco CP, Haley PJ, Friedman SM, et al. Biology of TACE inhibition. Ann Rheum Dis 2001;60 Suppl 3:iii25-32.
34. Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H, et al. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl] sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-α-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther 2004;309:348-55.
35. Conway JG, Andrews RC, Beaudet B, Bickett DM, Boncek V, Brodie TA, et al. Inhibition of tumor necrosis factor-α (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases. J Pharmacol Exp Ther 2001;298:900-8.
36. Stewart K, Walsh S, Screen J, Jefferiss CM, Chainey J, Jordan GR, et al. Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J Bone Miner Res 1999;14:1345-56.
37. Towler DA, St. Arnaud R. Use of culture osteoblastic cells to identify and characterize transcriptional regulatory complexes. In: Principles of bone biology. 2nd ed. Vol. 2. New York: Academic Press; 2002. p. 1503-27.
38. Franchimont N, Gangji V, Durant D, Canalis E. Interleukin-6 with its soluble receptor enhances the expression of insulin-like growth factor-I in osteoblasts. Endocrinology 1997;138:5248-55.
39. Delidow BC., Lynch JP, Peluso JJ, White B. Polymerase chain reaction. In: Harwood A, editor. Methods in molecular biology. Vol. 58. Basic DNA and RNA protocols. Totowa (NJ): Humana Press; 1996. p. 275-92.
40. Bonizzi G, Piette J, Schoonbroodt S, Merville MP, Bours V. Role of the protein kinase C λ/ι isoform in nuclear factor-κB activation by interleukin-1β and tumor necrosis factor-α: cell type specificities. Biochem Pharmacol 1999;57:713-20.
41. Scherr M, Morgan MA, Eder M. Gene silencing mediated by small interfering RNAs in mammalian cells. Curr Med Chem 2003;10:245-56.
42. Schooltink H, Stoyan T, Lenz D, Schmitz H, Hirano T, Kishimoto T, et al. Structural and functional studies on the human hepatic interleukin-6 receptor: molecular cloning and overexpression in HepG2 cells. Biochem J 1991;277:659-64.
43. Itai T, Tanaka M, Nagata S. Processing of tumor necrosis factor by the membrane-bound TNF-α-converting enzyme, but not its truncated soluble form. Eur J Biochem 2001;268:2074-82.
44. 2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells. Eur J Immunol 1998;28:3514-22.
45. Doedens JR, Black RA. Stimulation-induced down-regulation of tumor necrosis factor-α converting enzyme. J Biol Chem 2000;275:14598-607.
46. Zhang Z, Kolls JK, Oliver P, Good D, Schwarzenberger PO, Joshi MS, et al. Activation of tumor necrosis factor-α-converting enzyme-mediated ectodomain shedding by nitric oxide. J Biol Chem 2000;275:15839-44.
47. Fan H, Turck CW, Derynck R. Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-α converting, enzyme and of an alternatively translated polypeptide. J Biol Chem 2003;278:18617-27.
48. Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin-6 receptor shedding. J Exp Med 1999;189:599-604.
49. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997;15:797-819.
50. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-8.
51. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, et al. An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281-4.
52. Boissy P, Lenhard TR, Kirkegaard T, Peschon JJ, Black RA, Delaisse JM, et al. An assessment of ADAMs in bone cells: absence of TACE activity prevents osteoclast recruitment and the formation of the marrow cavity in developing long bones. FEBS Lett 2003;553:257-61.
53. Black RA, White JM. ADAMs: focus on the protease domain. Curr Opin Cell Biol 1998;10:654-9.
54. Chesneau V, Becherer JD, Zheng Y, Erdjument-Bromage H, Tempst P, Blobel CP. Catalytic properties of ADAM19. J Biol Chem 2003;278:22331-40.